Scientific Advisory Board

The Scientific Advisory Board provides oversight for product development within GB Sciences’ intellectual property portfolio, consisting of five original patent applications, one licensed patent application, and one licensed approved patent. GB Sciences remains committed to discovering novel cannabis-based therapies for disease-specific applications; as well as producing standardized patent-pending formulations and ensuring their efficacy through well-controlled clinical trials. The Scientific Advisory Board will be tasked with efficiently managing GB Sciences’ resources while creating and testing their proprietary cannabis-based formulas.

Dr. Andrea Small-Howard

Chief Science Officer

Dr. Helen Turner

VP Innovation, Dean of Natural Sciences & Mathematics, Chaminade University

Dr. Norbert E. Kaminski

Professor, Department of Pharmacology & Toxicology, MSU

Dr. Carlos F. Rios-Bedoya

Corporate Director of Scholarly Inquiry, McLaren Health

Dr. Zoltan Mari

Director of the PD and Movement Disorders Program and The Ruvo Family Chair, Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, NV

Dr. Alexander Stokes

Assoc. Professor, Univ. of Hawaii-John A Burns School of Medicine, Center for Cardiovascular Research